<DOC>
	<DOCNO>NCT03065790</DOCNO>
	<brief_summary>Adult patient non-Hodgkin lymphoma treat lenalidomide undergo FDG PET/CT scan early evaluation response therapy . Changes FDG uptake correlate response long term outcome .</brief_summary>
	<brief_title>Early FDG PET/CT Imaging Measure Response Patients With Non-Hodgkin Lymphoma Lenalidomide</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Adult patient , least 18 year age History histologically confirm NHL assess per medical record review . At least one site measurable disease ( per RECIST 1.1 ) see CT , MRI , FDG PET/CT . Recommended start lenalidomide . Participants must inform investigational nature study provide write informed consent accordance institutional federal guideline prior studyspecific procedure . Females pregnant breastfeeding time screen eligible study . Female participant childbearing potential urine serum pregnancy test time screen visit . Inability tolerate image procedure opinion investigator treat physician . Serious unstable medical psychological condition , opinion investigator would compromise subject 's safety successful participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>